Key clinical point: Dupilumab has been found effective in two phase 3 trials for treating severe chronic rhinosinusitus with nasal polyps.
Major finding: Relative to placebo, dupilumab reduced the nasal polyp score, the primary outcome, by 2.06 and 1.8 (both P less than .0001) in the trials.
Data Source: Two phase 3 double-blind, placebo-controlled multicenter randomized trials.
Disclosures: Dr. Máspero reports no potential conflicts of interest.
Bachert C et al. Lancet. 2019 Sep 26. doi: 10.1016/S0140-6736(19)31881-1.